A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD
Pulmonary arterial hypertension (PAH) is a frequent complication of congenital heart disease as a co...
AbstractDespite significant advances in pharmacological treatments, pulmonary arterial hypertension ...
Aims: Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD-PA...
A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) re...
A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) re...
Object: Due to substantial progress of medications to treat pulmonary arterial hypertension (PAH), c...
Large left to right shunt across an atrial septal defect results in volume overload and dilatation o...
Atrial septal defects (ASDs) are one of the most common forms of congenital cardiac lesions diagnose...
Atrial septal defects (ASDs) are one of the most frequent congenital cardiac malformations, accounti...
Background/objectives Pulmonary arterial hypertension is an important complication in hemodynamicall...
Beyond medical therapy, different interventional and surgical approaches exist for treatment of pulm...
Pulmonary arterial hypertension (PAH) is a severe and rapidly progressive condition, ultimately lead...
AbstractBeyond medical therapy, different interventional and surgical approaches exist for treatment...
BACKGROUND Pulmonary hypertension (PH), recently redefined as mean pulmonary arterial pressure >2...
BACKGROUND Pulmonary hypertension (PH), recently redefined as mean pulmonary arterial pressure >2...
Pulmonary arterial hypertension (PAH) is a frequent complication of congenital heart disease as a co...
AbstractDespite significant advances in pharmacological treatments, pulmonary arterial hypertension ...
Aims: Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD-PA...
A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) re...
A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) re...
Object: Due to substantial progress of medications to treat pulmonary arterial hypertension (PAH), c...
Large left to right shunt across an atrial septal defect results in volume overload and dilatation o...
Atrial septal defects (ASDs) are one of the most common forms of congenital cardiac lesions diagnose...
Atrial septal defects (ASDs) are one of the most frequent congenital cardiac malformations, accounti...
Background/objectives Pulmonary arterial hypertension is an important complication in hemodynamicall...
Beyond medical therapy, different interventional and surgical approaches exist for treatment of pulm...
Pulmonary arterial hypertension (PAH) is a severe and rapidly progressive condition, ultimately lead...
AbstractBeyond medical therapy, different interventional and surgical approaches exist for treatment...
BACKGROUND Pulmonary hypertension (PH), recently redefined as mean pulmonary arterial pressure >2...
BACKGROUND Pulmonary hypertension (PH), recently redefined as mean pulmonary arterial pressure >2...
Pulmonary arterial hypertension (PAH) is a frequent complication of congenital heart disease as a co...
AbstractDespite significant advances in pharmacological treatments, pulmonary arterial hypertension ...
Aims: Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD-PA...